AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Moderna, Inc. Director's Dealing 2024

Dec 6, 2024

30610_dirs_2024-12-06_af7673f2-9b67-4ae3-a74f-3323c9e847bb.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2024-12-05

Reporting Person: Klinger Shannon Thyme (Chief Legal Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-12-05	Restricted Stock Units	$0	A	188761	Acquired		Common Stock (188761)	Direct

Footnotes

F1: 25% of the shares subject to this restricted stock unit award will vest on December 5, 2025, with the remainder vesting in twelve (12) equal quarterly installments thereafter.